GEN Exclusives

More »

GEN News Highlights

More »
Jul 11, 2013

AB Sciex, Beckman Coulter Combining Chromatography, CE Businesses

  • Analytical technologies firm AB Sciex is combining its chromatography business with Beckman Coulter Life Sciences' capillary electrophoresis (CE) business with the aim of advancing separations science. This move, the companies say, will merge Beckman Coulter’s knowledge of microscale separation with the expertise in microfluidics of AB Sciex' Eksigent chromatography team.

    This combination will include the transition of personnel as well as CE technologies and resources from Beckman Coulter Life Sciences to AB Sciex, both of which are owned by Danaher. The current plan is to have the Sciex separations business manage both the standalone Beckman Coulter CE products and the integrated CE-MS technology by the end of Q3. The CE products will continue to be branded "Beckman Coulter," and the separations business will also continue to manage all chromatography products, including Eksigent nano LC and micro LC systems, chips, software, and columns.

    The firms say this new alignment will enable better serving of customers while addressing analytical challenges with powerful scientific strategies that take advantage of complementary technologies.

    "We are bringing together the best in CE with the best in nano LC and micro LC as a unified team to broaden the range of solutions available to our customers," said Rainer Blair, president of AB Sciex. "By integrating the Beckman Coulter CE team into the Sciex separations business, we will be able to take CE and our chromatography solutions to a whole new level."

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »